MIRA — MIRA PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1904286 ·
Last close
$0.64
Market Cap
$26.89M
52W High
$1.69
52W Low
$0.51
ADV30
132,121
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -1,412,028 | -1,422,732 | 7,267,384 | 2,504,631 | 426,176 |
| Jun 2026 | 0 | — | -1,156,119 | -1,208,534 | 8,203,140 | 3,609,442 | 40,823 |
| Mar 2026 | 0 | — | -1,103,479 | -1,150,152 | 9,463,736 | 4,815,031 | 114,761 |
| Dec 2025 | 0 | — | -5,824,827 | -5,983,321 | 11,093,605 | 6,346,921 | 702,068 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,638,863
Investing CF
—
Financing CF
$7,517,830
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.33
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-41,938,892
Inventory
—
Receivables
—
ST Investments
$4,503,973
EBIT TTM
$-9,401,410
Pretax Income TTM
$-9,479,680
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,493,112 | -10,442,485 | 11,093,605 | 702,068 | 10,391,537 | -4,661,669 |
| Dec 2024 | 0 | -8,018,328 | -7,852,659 | 2,923,099 | 723,349 | 2,199,750 | -5,560,606 |
| Dec 2023 | 0 | -8,526,049 | -11,982,343 | 4,932,443 | 558,097 | 4,374,346 | -4,532,403 |
| Dec 2022 | 0 | -7,047,940 | -7,058,190 | 858,074 | 1,454,306 | -596,232 | -5,604,759 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-9,479,680
OpCashFlow TTM
—
Assets (Latest)
$8,203,140
Forward EPS
$-0.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MCUJF | MEDICURE INC | $27.45M | $2.63 | — |
| RMTI | ROCKWELL MEDICAL, INC. | $26.25M | $6.61 | — |
| BHST | BIOHARVEST SCIENCES INC. | $27.65M | $1.22 | — |
| ACET | Adicet Bio, Inc. | $26.03M | $2.78 | — |
| BETRF | BetterLife Pharma Inc. | $25.64M | $0.15 | — |
News headlines (Yahoo Finance, 1h cache)
MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
2026-11-17 13:00 · Yahoo
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
2026-10-29 12:00 · Yahoo
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
2026-10-22 12:00 · Yahoo
Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
2026-09-01 12:04 · Yahoo
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
2026-09-01 12:00 · Yahoo
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
2026-07-30 12:00 · Yahoo
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
2026-07-06 13:00 · Yahoo
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
2026-06-25 12:15 · Yahoo
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
2026-06-17 12:00 · Yahoo
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
2026-06-04 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.